BioSpace News Archive

Humacyte, Inc. (Nasdaq: HUMA), today announced that six-month outcomes from a preclinical study of a small diameter Human Acellular Vessel™ (HAVTM) in coronary artery bypass grafting will be presented at the Basic Cardiovascular Sciences (BCVS) Scientific Sessions taking place in Chicago, IL July 25-28, 2022.

Umbra Applied Technologies Group, Inc. announced that its subsidiary Ossifix Orthopedics has added a new product to its expanding suite of orthopedic products.

Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the first subject has been dosed in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.

Packaging of pharmaceutical products is considered to be a very crucial element for the pharmaceutical industry because such packaging ensures the quality and safety of drugs that it contains.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Two major user propositions for deploying healthcare virtual assistants market are their imprint on reducing the burden of care teams and improved patient experience.

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to June 2022.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the formation of a Medical Advisory Board, and the appointment of Dr. Timothy Wang as its inaugural member.

Paragraf, the first company in the world to deliver a scalable approach to graphene electronic device manufacturing, announces a plan to develop a new generation of graphene-based, in-vitro diagnostic products that will give results within a few minutes.

Swedish Orphan Biovitrum AB announced its report for the second quarter of 2022

REPO4EU consortium seeks to address the urgent need for new cost-effective therapies, as well as to improve existing treatments through international cooperation, pooling research and innovation expertise.